Researchers find diabetes in obese no less likely to escape diagnosis
NEW YORK Researchers from the Harvard Medical School and Boston’s Beth Israel Deaconess Medical Center have found that diabetes in obese people is as likely to dodge diagnosis as it is in slim people.
While being obese increases the chances of developing diabetes, the researchers reported in the September issue of the journal Diabetes Care, that it did not increase the chances that the diabetes will be diagnosed.
The researchers examined data on 5,514 people who participated in the National Health and Nutrition Examination Survey between 1999 and 2004. They found that 10 percent of survey participants had diabetes, and 28 percent had not been diagnosed. There was no statistical significance, however, between participants’ body-mass index and the likelihood that they would be diagnosed.
Teva’s Azilect slows Parkinson’s disease in trials
WASHINGTON Results from a Phase III clinical trial have shown that Teva Pharmaceutical’s Azilect 1-mg tablets can slow the progression of the disease, the drug maker announced.
Researchers gave 1,176 Parkinson’s disease patients daily 1- to 2-mg doses of Azilect for 18 months or a placebo for the first nine months and the drug for the second nine months.
Patients who took the 1-mg dose of Azilect showed significant improvement compared with patients in the placebo group.
The Food and Drug Administration approved Azilect in May 2006 as a monotherapy for early-stage ParkinsonOs disease and as an adjunct therapy to levodopa in moderate-to-advanced stages of the disease.
The drug, known generically as rasagiline mesylate, is available in 30 countries. Danish drug maker Lundbeck markets it in Europe, and both companies plan to co-promote it in the United Kingdom, Germany and France.
Taro to ask for extension on Sun Pharmaceuticals’ offer
TEL AVIV,, Israel Taro Pharmaceutical Industries has said it will appeal to Israel’s Supreme Court to contest a ruling in the Tel Aviv District Court regarding India-based Sun Pharmaceuticals’ offer to acquire the Israeli generic drug maker.
The District Court judge had called Taro’s demand for a tender offer from Sun disingenuous, considering Taro’s acceptance of the offer a year ago.
Taro plans to ask the Supreme Court to extend the deadline for Sun’s offer, which was Tuesday at 5 p.m.